The method of any one of embodiments 118-137, wherein the composition comprises between about 0.0001% to about 20% by weight of the therapeutic agent, about 0.0001% to about 15% by weight of the therapeutic agent, about 0.0001% to about 10% by weight of the therapeutic agent, about 0.0001% to about 5% by weight of the therapeutic agent therapeutic agent, or about 0.0001% to about 1% by weight of the therapeutic agent
Whitney Evans, PhD, RD, Director of Scientific Affairs at Danone, said: GLP-1 medications can lead to substantial weight loss, but they can also create unique nutrition challenges as they can substantially reduce food and calorie intake but do not change essential nutrient needs
A Thoughtful, Medical Approach At Musuma, hormone replacement therapy is never one-size-fits-all
If the patient was not capable of providing informed consent, written consent was obtained from the patient's representative and assent was received from the patient
